The main power of PRACTICAL is its capability to combine a large amount of data to provide a reliable assessment of the PrCa cancer risks. PRACTICAL has been involved in different projects of large scale validation of GWASes and also in large scale Gen-epi studies, fine mapping and candidate studies with other cancer consortia (as in the multi-cancer iCOGS and current OncoArray projects). You can discover more about our present and previous projects by following the menu links on the right.

Through these different projects, PRACTICAL has been able to identify a total of 47 single nucleotide polymorphisms (SNPs) from them known SNPs, that are associated with PCa risk.

PRACTICAL is also linked to clinical studies, in particular the Clinical ELLIPSE consortium (CEC, for disease management) and the IMPACT study (for targeted screening in BRCA1 and BRCA2 mutation carriers and controls).